anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a cosmetic material that keeps excellent skin touch, has excellent moisture retention and water retention ability and prevents deterioration of dermal connective tissue and a cosmetic containing the cosmetic material.  <P>SOLUTION: The cosmetic material and the cosmetic each contains a black swine-derived animal collagen. Ocean deep water much containing minerals is used as purified water as a base. The cosmetic material has high moisture retaining and water retaining effect and contains muscovado and squalane oil for supplying components necessary for the skin. The cosmetic (especially skin lotion or cosmetic cream) contains the cosmetic material.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PURPOSE: To obtain a preparation containing the cells (their treated products) of a lactic acid bacterium as an active ingredient, free from a side effect and toxicity, and enabling the rapid therapy of chronic active C type hepatitis by the oral administration of the preparation. CONSTITUTION: The preparation contains the cells of a lactic acid bacterium or their treated products, preferably comprising the cells of a microorganism [e.g. Enterococcus faecalis NF-1011 (FERM P-12564)] belonging to the genus Enterococcus, as an active ingredient. For the production of the preparation, a carrier such as starch, lactose or soybean protein, and additives such as an excipient, a binder, a disintegrator, a lubricant, a stabilizer and a flavor are used. The preparation is usually administered at a dose of 2-100mg/kg body weight/day as the active ingredient in one to several portions. The preparation can be used together with other medicines, and is effective also for a patient not exhibiting an effect on an INF therapeutic method.
Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years. Patients also undergo CT, MRI, and/or ultrasound throughout the trial and undergo bone marrow aspiration, bone marrow biopsy, and tumor biopsy at screening and time of progression.
Provided are conjugates useful in cancer, cardiovascular or infectious disease detection and/or therapy. The conjugate is of a ligand and protein. The ligand has a moiety capable of binding to mercapto groups and is capable of chelating a metal useful for detection or therapy. The protein reacts with a substance associated with a targeted cell, pathologic lesion or pathogen. The protein prior to conjugation has at least one mercapto group which becomes a site for conjugation to the ligand. Also provided are metal chelates of the conjugate, methods of detection and therapy, methods for producing the conjugate and pharmaceutical compositions of the conjugates.
The invention relates to linear ligand epitopes of bursal disease viruses, and a concrete use thereof. A polypeptide P22 of an infectious bursal disease virus (IBDV) VP2 protein is synthesized. Chicken embryo fibroblasts (CEFs) are utilized as target cells. Through infection and harvest of IBDV, virulence, a median tissue culture infective dose and an infection ratio of the IBDV are determined. A test of binding the synthesized polypeptide and the target cells, a test of blocking viruses and a test of blocking target cell infection caused by the IBDV through the synthesized polypeptide are carried out to screen specific binding target cells capable of inhibiting that viruses infect ligand epitope polypeptide and realizing accuracy positioning of IBDV ligand epitopes. The polypeptide P22 can inhibit that the IBDVs infect the CEFs, and a CEF infection rate is reduced when polypeptide concentration is increased. The polypeptide P22 has dose dependence. When polypeptide concentration is 0.2 mmol/L, the polypeptide P22 can completely inhibit that the IBDVs infect the CEFs. The chicken infectious bursal disease virus IBDV VP2 protein ligand binding epitope polypeptide further provides theoretical bases for a virus ligand epitope research based on interaction between virus ligands and virus receptors.
This experimental, prospective, and randomized controlled study was designed to determine and compare the effects of applying manual pressure and ShotBlocker methods in reducing pain and fear during the subcutaneous insulin injection for children with Type 1 diabetes mellitus. A parallel trial design was used describing two intervention (manual pressure and ShotBlocker) and a control group (no intervention used) as the third arm. The study sample composed of 90 children based on confidence interval of 95% and statistical power of 80%. In post-hoc analysis made using G power 3.1 software, the power of sample size including 90 children with α = .05 and effect size (w)= .31, was 1 - β = 0.87. Power of .80 or higher is indicative of an adequate sample size. In addition, in order to prevent bias and increase the validity of the data, the pain and fear scores of the children before and after the procedure were assessed by three different groups as children (n:90), their parents (n:90), and a researcher specialized in pediatric nursing (the first author; n:1), and the inter-observer agreement was examined. The parents meeting the following inclusion criteria were eligible for the participation: 1) being healthy in terms of neurological functions, 2) communicating verbally, 3) understanding and reading Turkish, and 4) voluntarily signing the written informed consent. The children were first categorized according to their genders and then assigned into three study groups by using block randomization method to control the effect of gender on pain. First, the numbers 1, 2 and 3, representing the three groups, were written on paper of the same color and shape and put in a pink box for girls and blue for boys.After, female children were asked to draw a piece of paper from the pink box and male children were asked to draw a piece of paper from the blue box to provide a randomized distribution and to reduce all negative effects. Thus, the groups became self-balanced. Intervention and control groups were matched in themselves based on gender, each group included a total of 30 children including 15 girls and 15 boys. The study was conducted in accordance with the CONSORT guideline for reporting the randomized controlled trials.
This disclosure relates to a system configured to facilitate a personal data market in which personal data is transacted. The system comprises one or more processors configured to execute computer program modules. The system is configured to aggregate personal data from one or more personal data sources and classified the personal data. The personal data comprises a plurality of units associated with one or more people. The system is configured to present the aggregated and classified personal data to users and manage transactions of the personal data. A given transaction comprises a transfer of one or more units of personal data associated with one or more people to a requestor computing platform in exchange for an amount of compensation.
This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
Since the patients included in the study were discharged early (mean hospitalization duration was 3 days), the first, third and fifth SC heparin injection (0.6 ml) administrations were performed by the researcher for three days. The application was made to the arm area due to the fact that Shotblocker was difficult to place in the abdominal area, and the outer side of the arm was preferred for subcutaneous injection administrations in the clinic where the study was conducted. Shotblocker was placed on the injection site determined on the outer side of the upper arm of the patient and the injection was administered by gently pressing the tool with the fingertips during the injection. Shotblocker was removed after removal of the injector. Injections were completed in 20 seconds and the injection site was supported with cotton for 30 seconds.
Elderly patients undergoing major, orthopedic surgery are at risk of developing postoperative cognitive dysfunction (POCD) or memory impairment following surgery. Transcranial doppler (TCD) monitoring of blood flow to the brain has detected cerebral emboli in 60% of patients following release of the thigh tourniquet during total knee replacement or arthroplasty (TKA). These cerebral embolic events may represent one of the mechanisms responsible for postoperative cognitive problems.

The standard surgical technique for TKA involves cleaning the bone surfaces with pulsed saline lavage prior to cementation and prosthesis insertion. The CarboJet Assisted technique utilizes carbon dioxide lavage to clean and dry the femur canal and bone surfaces prior to cementation and implantation. Because it removes fat globules and marrow particulates from the bone surfaces, it is hypothesized that the use of a carbon dioxide lavage technique in TKA will result in fewer thromboembolic events and increased cement penetration compared with the standard technique using pulsed saline lavage. Cement penetration affects the strength of the bone-cement interface and, therefore, contributes to implant longevity.
BACKGROUND: The double-opposing Z-plasty is a fundamental approach for cleft palate repair. Recently, some surgeons have begun implementing a single Z-Plasty, igniting discussions on the most effective technique for enhancing postoperative outcomes. Consequently, this study sought to evaluate the outcomes of employing single and double Z-plasties within the modified Sommerlad-Furlow technique.
METHODS: 116 cleft palate patients undergoing primary surgical repair were divided into two groups: those treated with the Sommerlad-Furlow method using a double-opposing Z-plasty (S.F.2.Z.P. group, n = 58) and those receiving a single nasal Z-plasty (S.F.1.Z.P. group, n = 58). Data on cleft type and width, soft palate length, palatal fistula, and velopharyngeal function were collected. Mann-Whitney test compared the mean values between groups.
RESULTS: The S.F.2ZP group demonstrated a statistically significant increase in soft palate length compared to those in the S.F.1ZP group (p = 0.008). However, the S.F.1ZP group demonstrated adequate soft palate length (7.9 ± 2.8 mm) compared to the S.F.2ZP group (9.3 ± 2.8 mm). The velopharyngeal function was good in both groups, with no significant differences (P = 0.52). While the proper velopharyngeal closure was 81% in the S.F.1ZP group and 87.9% in the S.F.2ZP group, velopharyngeal insufficiency was 10.3% and 5.2%, respectively. The rates of persistent palatal fistula were 5.2% in the S.F.1ZP group and 3.4% in the S.F.2ZP group, with no significant differences found between both groups (P = 0.64).
CONCLUSIONS: There were no significant differences in crucial outcomes such as velopharyngeal function and the incidence of persistent palatal fistulas, indicating the effectiveness of both techniques. While the double-opposing Z-plasty demonstrated a statistically significant increase in soft palate length, the a nasal Z-plasty demonstrated adequate soft palate length which sufficiently enables effective velopharyngeal closure. These outcomes suggest that a single Z-plasty is both effective and easy to perform, making it a valuable surgical approach for achieving the desired outcomes..
CLINICAL RELEVANCE: The current study suggests that although the soft palate may not be as elongated with nasal Z-plasty alone compared to the double Z-plasty, it sufficiently enables effective velopharyngeal closure.
The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
The present invention relates to inflammation relieving powder (paste) for treating vasculitis. Giant knotweed rhizome, coptis, pearl powder, bletilla tuber, dragon's blood, borneol and dahurian angelica are used as raw materials, the effect and the functions of medicines are integrated, a pure traditional Chinese medicine preparation is prepared according to a reasonable formula, and then, gromweel oil is matched so that an external medicine is prepared. The powder (paste) has the functions of carrying out sterilization, relieving inflammation, stopping bleeding, regenerating the tissue and promoting granulation tissue growth, capillary vessel regeneration and amputated finger and toe regeneration. The powder (paste) is matched with an oral medicine for vasculitis to treat vasculitis gangrene, ulcers, trauma and scalds. The powder (paste) avoids amputation and has no toxic or side effect on a human body. The total effective rate is 90%, and the cure rate reaches more than 80%.
Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with placebo to be taken twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
INTRODUCTION: Despite research efforts, predicting Clostridioides difficile incidence and its outcomes remains challenging. The aim of this systematic review was to evaluate the performance of machine learning (ML) models in predicting C. difficile infection (CDI) incidence and complications using clinical data from electronic health records.
METHODS: We conducted a comprehensive search of databases (OVID, Embase, MEDLINE ALL, Web of Science, and Scopus) from inception up to September 2023. Studies employing ML techniques for predicting CDI or its complications were included. The primary outcome was the type and performance of ML models assessed using the area under the receiver operating characteristic curve.
RESULTS: Twelve retrospective studies that evaluated CDI incidence and/or outcomes were included. The most commonly used ML models were random forest and gradient boosting. The area under the receiver operating characteristic curve ranged from 0.60 to 0.81 for predicting CDI incidence, 0.59 to 0.80 for recurrence, and 0.64 to 0.88 for predicting complications. Advanced ML models demonstrated similar performance to traditional logistic regression. However, there was notable heterogeneity in defining CDI and the different outcomes, including incidence, recurrence, and complications, and a lack of external validation in most studies.
DISCUSSION: ML models show promise in predicting CDI incidence and outcomes. However, the observed heterogeneity in CDI definitions and the lack of real-world validation highlight challenges in clinical implementation. Future research should focus on external validation and the use of standardized definitions across studies.
A method of extracting cannabinoids, cannflavins, and/or essential oils from hemp and/or of producing a whole hemp extract lacking Δ 9 -THC is herein described. The industrial hemp is harvested and the chaff is threshed from the seeds. The chaff is then ground and the ground chaff is extracted with an organic solvent. The extract is then loaded onto a chromatographic column selected to fractionate specific cannabinoids, cannflavins, and essential oils. In one embodiment, Δ 9 -THC is fractionated out of the extract, producing a whole hemp extract lacking Δ 9 -THC. In other embodiments, specific cannabinoids and related compounds of interest are fractionated out, thereby producing purified cannabinoids, cannflavins, and related compounds.
This trial approach allows for detailed comparison of resected tissue samples, cerebrospinal fluid and blood of all patient groups. So, the investigators will investigate biomaterial of recently irradiated (neoadjuvant and intraoperative arms) and non-irradiated (adjuvant arm) tissue. All this prompts the main issues of the explorative randomized controlled phase 2 RADCAV trial: Is there a difference between neoadjuvant stereotactic radiotherapy vs. intraoperative radiotherapy vs. adjuvant stereotactic radiotherapy regarding the factors immune profiling, dosimetry, efficacy and toxicity. It can be hypothesized that the resected tissue differs between recently irradiated and non-irradiated brain metastases, for example regarding different histopathologic and molecular pathologic markers including immune environment, markers for cell death and markers for tumor invasion. Are there histopathologic and molecular pathologic markers of tumor cell response and prognosis so the investigators can better understand the effects of irradiation on metastatic brain tissue? And are there relevant differences in dosimetry that put patients at different risks for efficacy and toxicity?
Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
PURPOSE: An injection composition containing saponin Rg1 is provided to promote hair follicle growth and to ensure excellent hair growth without toxicity to human body. CONSTITUTION: An injection composition for hair growth contains saponin Rg1 as an active ingredient. The composition additionally contains saponin Rd or Rg3. The composition is a hypodermic injection composition. The injection composition is used together with pharmaceutically acceptable carrier, excipient, and diluents. The effective amount of saponin Rg1 is 30-1,000/mg per 1kg.
Clinic providers in Duke Rheumatology outside of the Duke Lupus Clinic are eligible to participate in the SLE@Duke intervention. Participants complete a baseline survey and training in the Type 1 \& 2 SLE Model. They are asked to perform the intervention for all eligible patients over 4 weeks. Patients complete a survey at the end of their clinic visit, and providers complete a survey at the end of the 4 week intervention period. All participating providers were invited to an in-depth interview at the end of the intervention period.
Prochieve® 4% is administered vaginally every other day up to a total of six doses. For women who fail to respond, a trial of Prochieve® 8% every other day up to a total of six doses may be instituted. 

It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.

SEE Prochieve® PATIENT INFORMATION SHEET - HOW TO USE Prochieve®.   
Note: The PATIENT INFORMATION SHEET contains special instructions for using the applicator at altitudes above 2500 feet in order to avoid a partial release of Prochieve® before vaginal insertion.
The invention discloses a method for extracting general flavone from sorrel shell waste residues through microwave refluxing. The method comprises the following specific steps of: 1, removing impurities from naturally-dried sorrel shells, smashing, sieving with a sieve of 40-60 meshes, and putting into a constant-temperature drying oven for drying sorrel shell powder for later use; and 2, uniformly fixing the powder treated in the step 1 with 30-60 percent of ethanol in the weight volume ratio of 1:25-1:50, performing reflux leaching at microwave power for 10-25 minutes, performing suction filtration to obtain a general flavone extracting solution, removing ethanol by rotationally evaporating, and performing vacuum drying to obtain a general flavone solid. The content of general flavone in a concentrated solution is measured with an aluminum chloride colorimetric method. According to measurement, the extraction ratio of general flavone is 95 percent, and the yield is 0.20 percent. The method has the advantages of quickness, high extraction ratio, environmental friendliness and nontoxicity by taking ethanol water as a solvent, simple equipment operation, small solvent using amount, easiness for recovering and suitability for expanded production in plants. The method has wide application prospects in medicines and foods.